MedTrace Logo

TRAP Study: Testosterone for Androgen Receptor Polymorphism

NCT06195163 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-05-09

No results posted yet for this study

Summary

To determine whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes (COCs) obtained after ovarian stimulation by more than 1.5 in patients with low ovarian reserve and androgen receptor polymorphism undergoing intracytoplasmic sperm injection (ICSI).

Conditions

  • Fertility Disorders

Interventions

DRUG

Transdermal Gel in Sachet Dosage Form

Transdermal testosterone gel application prior to ovarian stimulation in the study group.

DRUG

No pretreatment

No pretreatment prior to the ovarian stimulation in the control group.

Sponsors & Collaborators

  • Instituto Bernabeu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06195163 on ClinicalTrials.gov